Eli Lilly and Company
LLY
$659.00
$19.573.06%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.26B | 49.00B | 45.04B | 40.86B | 38.92B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.26B | 49.00B | 45.04B | 40.86B | 38.92B |
| Cost of Revenue | 9.25B | 8.97B | 8.42B | 7.80B | 7.49B |
| Gross Profit | 44.01B | 40.03B | 36.62B | 33.06B | 31.43B |
| SG&A Expenses | 9.30B | 8.66B | 8.13B | 7.63B | 7.34B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.38B | 28.83B | 27.54B | 25.97B | 25.03B |
| Operating Income | 22.88B | 20.17B | 17.50B | 14.90B | 13.89B |
| Income Before Tax | 16.86B | 13.60B | 12.68B | 10.15B | 8.99B |
| Income Tax Expenses | 3.06B | 2.49B | 2.09B | 1.78B | 1.65B |
| Earnings from Continuing Operations | 13.80K | 11.11K | 10.59K | 8.37K | 7.34K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.80B | 11.11B | 10.59B | 8.37B | 7.34B |
| EBIT | 22.88B | 20.17B | 17.50B | 14.90B | 13.89B |
| EBITDA | 24.78B | 22.00B | 19.27B | 16.57B | 15.50B |
| EPS Basic | 15.33 | 12.32 | 11.74 | 9.28 | 8.14 |
| Normalized Basic EPS | 15.28 | 13.49 | 11.69 | 9.95 | 9.32 |
| EPS Diluted | 15.30 | 12.29 | 11.71 | 9.25 | 8.12 |
| Normalized Diluted EPS | 15.25 | 13.46 | 11.66 | 9.92 | 9.30 |
| Average Basic Shares Outstanding | 3.60B | 3.60B | 3.61B | 3.61B | 3.61B |
| Average Diluted Shares Outstanding | 3.61B | 3.61B | 3.62B | 3.62B | 3.61B |
| Dividend Per Share | 5.60 | 5.40 | 5.20 | 5.03 | 4.86 |
| Payout Ratio | 36.46% | 43.74% | 44.20% | 54.12% | 59.60% |